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Urinary Incontinence (MUI) and Urge Urinary Incontinence
(UUI) in Germany over 12 months. METHODS: PURE is an
ongoing six-month, pan-European, prospective observational
study to determine direct treatment costs for women with UI.
Analysis includes 2175 German patients (mean age 65.1 years)
with SUI (n = 487), MUI (n = 1457) or UUI (n = 231) symptoms.
Participating investigators are ofﬁce based primary care physi-
cians (n = 110), urologists (n = 185), gynaecologists (n = 100)
and other (n = 4). Resource use data for cost estimation was col-
lected retrospectively including medication, conservative treat-
ment, diagnostic and surgical procedures, incontinence products
and visits to health care providers for 12 months preceding base-
line. Unit costs for 2004 from the perspective of statutory health
insurance (SHI) were used. RESULTS: Average total annual costs
for women with UI ranged from 413.0€ for SUI, 438.0€ for UUI
to 585.2€ for MUI. Costs were primarily attributable to pad
costs for SUI (223.5€), MUI (300.3€) and UUI (235.0€). A total
of 52.4% of pad costs were incurred by SHI, with remaining
costs being paid out-of-pocket. Average drug costs were 47.4€
for SUI, 86.1€ for MUI and 107.2€ for UUI. Patients receiving
UI surgery had average surgical costs of 3326.9€. On average,
26.9% of patients with SUI, 44.0% with MUI and 52.8% with
UUI were treated with UI medication, while 10.3% of patients
with SUI, 16.8% with MUI and 17.5% with UUI were ever
treated with surgery. Pad use ranged from 85%, 87.2% to 89.2%
in SUI, MUI and UUI patients, respectively. CONCLUSION:
Patients with MUI were found to incur the highest costs com-
pared to patients with other UI subtypes. Patients with SUI were
treated with UI medication not indicated for use in SUI. Inci-
dence of previous UI surgery was considerable in this treatment
seeking population.
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OBJECTIVE: Over 75% of individuals with Alzheimer’s disease
(AD) residing in nursing homes have behavioral and psycholog-
ical signs of dementia (BPSD). Quetiapine is an atypical antipsy-
chotic that has demonstrated effectiveness in the treatment of
BPSD. This analysis examines the health economic implications
of treating patients with AD and BPSD with quetiapine at a dose
of 200mg per day. METHODS: A discrete event simulation was
developed to compare treatment of institutionalized AD patients
in the US with quetiapine relative to no pharmacological treat-
ment. The model follows individuals over one year, tracking
changes in BPSD and the resulting inﬂuence on costs. Effective-
ness and treatment persistence estimates are based on a ran-
domized, double-blind trial comparing quetiapine to placebo,
while BPSD related nursing home costs are derived from the
Minnesota Case Mix Research Database and published infor-
mation. Costs in the simulation, which are reported in 2004 US
dollars, include nursing home per diems, physician visits, psy-
chiatric and behavioral services, and treatment with quetiapine.
The primary effectiveness outcome is time without clinically sig-
niﬁcant BPSD. RESULTS: Untreated patients incur costs averag-
ing $49,350 per year, clinically signiﬁcant BPSD apparent 87%
of the time. Treatment with quetiapine costs $1142 per year, but
this is entirely offset in savings from other areas, resulting in net
savings of $44 per year. At the same time, patients spend seven
fewer weeks with clinically signiﬁcant BPSD. In repeated simu-
lations, quetiapine dominated no treatment in almost 60% of
replications. In 94% of replications, quetiapine was either dom-
inant or led to incremental costs per BPSD year avoided of under
$5000. Sensitivity analyses showed that variations in BPSD-
speciﬁc nursing home costs had the strongest impact on out-
comes. CONCLUSIONS: These analyses indicate that quetiap-
ine in patients with AD and BPSD is cost-effective and may even
lead to overall health care system savings.
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OBJECTIVE: To assess whether comparable populations can be
created to assess the economic impact of different treatment
strategies for overactive bladder (OAB). METHODS: Data 
were obtained from the PharMetrics Patient-Centric Database 
on patients diagnosed with OAB between January, 2001 and
December, 2002. Patients were stratiﬁed into those receiving a
pharmacological therapy for OAB (ie, long-acting tolterodine,
immediate- or extended-release oxybutynin) versus medical 
management alone. Patients were matched 1 :1 by the estimated
propensity score for OAB pharmacotherapy. A logistic regression
model included selected demographic and clinical characteristics.
A ﬁtted probability of receipt of OAB medication was generated
for all patients, and matching was performed based on a differ-
ence of ± 0.01 in this probability. Differences in patient charac-
teristics as well as outcomes and costs during follow-up were
assessed using descriptive statistics (chi-squares for proportions,
Wilcoxon rank-sum tests for continuous variables). RESULTS:
A total of 29,992 matched pairs were identiﬁed. Patients aver-
aged 50 years of age, and 75% were women. After matching,
differences in all patient characteristics were nonsigniﬁcant, with
the exception of physician specialty. Both groups had a pre-index
Charlson Comorbidity Index of 0.70. The incidence of urinary
tract infection was higher in the group receiving medical man-
agement alone (27.4% vs. 20.2%, p < 0.0001). Mean (± SD)
OAB-related costs were also signiﬁcantly higher in the medical
management group ($454 ± $2559 vs. $253 ± $1985, p <
0.0001). Pharmacy costs were higher in the drug-treated group,
but total costs (OAB-related and unrelated) were numerically
similar ($8666 ± $22,757 vs. $8674 ± $20,496), suggesting that
high pharmacological costs of treatment are offset by reduction
in other OAB- and infection-related costs. CONCLUSIONS:
Creation of comparable cohorts is feasible, even when treatment
interventions differ substantially. Furthermore, OAB pharma-
cotherapy appears to be cost-neutral in the management of the
condition, and may impart selected clinical beneﬁts.
CS8
ECONOMIC EVALUATION OF ONDANSETRON VERSUS
DIMENHYDRINATE FOR PREVENTION OF POSTOPERATIVE
VOMITING IN CHILDREN
Piwko C1, Lasry A1,Alanezi K1, Coyte PC1, Ungar WJ2
1University of Toronto,Toronto, ON, Canada; 2The Hospital for Sick
Children,Toronto, ON, Canada
OBJECTIVE: Postoperative vomiting (POV) is a distressing com-
plication and its incidence ranges from 34%–90% in children
undergoing strabismus surgery when antiemetics are not ad-
ministered prophylactically. This study compares the economic
beneﬁt of ondansetron versus dimenhydrinate as antiemetics
administered prophylactically in children undergoing strabismus
surgery. METHODS: This study, conducted at Toronto’s Hospi-
